Protecting functional β cells with a therapeutic peptide

Meghan L. Marré¹, Jon D. Piganelli¹, Eddie A. James²

¹Division of Pediatric Surgery, Department of Surgery, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; ²Benaroya Research Institute at Virginia Mason, Seattle, WA, USA

Correspondence to: Jon D. Piganelli. 4401 Penn Avenue, Pittsburgh, PA 15224, USA. Email: jdp51@pitt.edu; Eddie A. James. Benaroya Research Institute at Virginia Mason, 1201 9th Ave., Seattle, WA 98101-2795, USA. Email: ejames@benaroyaresearch.org.

Provenance: This is a Guest Editorial commissioned by Section Editor You-Fan Peng, MD, PhD (Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China).


Submitted Jul 20, 2018. Accepted for publication Jul 24, 2018.
doi: 10.21037/atm.2018.07.26

Type 1 diabetes (T1D) is an autoimmune disease in which insulin-producing pancreatic islet β cells are targeted and destroyed by autoreactive immune cells. This loss of β cell mass leads to decreased capacity for insulin production and an eventual decline of insulin-mediated regulation of glucose levels in the blood. As functional β cell mass is depleted, the remaining β cells are required to produce higher levels of insulin per β cell, leading to β cell exhaustion or apoptosis, both of which lead to further decreases in net β cell function (1). Eventually, too few functional β cells remain to secrete adequate levels of insulin to maintain normal blood glucose levels. Insufficient insulin secretion then leads to chronic hyperglycemia and T1D. T1D can be managed through injection of exogenous insulin to normalize blood glucose. However, no cure exists and insulin therapy leaves patients susceptible to hypoglycemic episodes and to the deleterious complications of periodic hyperglycemia including cardiovascular disease, blindness, and kidney failure (2).

Destruction of β cell mass has long been viewed as the predominant cause of T1D. This destruction is believed to occur gradually and as a result of chronic and prolonged autoimmune activity in the islet (3,4). The characteristic hyperglycemia and related symptoms associated with T1D are not thought to occur until approximately 80% of functional β cell mass is lost (5). However, several studies provide evidence that a significant proportion of subjects diagnosed with T1D have measurable levels of c-peptide, indicating a residual mass of functional β cells (5). Notably, some subjects retain measurable β cell functional for years after diagnosis. Furthermore, an even larger proportion of subjects with T1D (including subjects with no detectable c-peptide) secrete measurable levels of proinsulin, indicating the presence of significant β cell mass that is dysfunctional but not destroyed (6). As such, there is an increasing interest in more clearly defining the role that β cell dysfunction plays in the progression of T1D and, correspondingly, the importance of developing therapeutic strategies to restore β cell health and function. Indeed, there is an apparent window of opportunity between the initiation of autoimmune activity and the clinical onset of T1D for novel therapeutic interventions to rejuvenate and protect remaining β cell mass, thereby delaying T1D onset (7).

The primary role of β cells is secretion of insulin in response to increased blood glucose. Insulin is stored in secretory granules and is released by exocytosis. This release, then, requires the fusion of insulin-containing granules with the plasma membrane. The fusion of these membranes is accomplished by assembly of soluble N-ethylmaleimide-sensitive factor-attachment protein receptor (SNARE) complexes. These membrane-bridging complexes are assembled from individual SNARE proteins anchored in the two membranes. In response to glucose sensing, two target membrane SNARE (t-SNARE) proteins on the plasma membrane, syntaxin and synaptosomal-associated protein 25 (SNAP25), bind with one vesicle-associated (v-SNARE) protein, vesicle-associated membrane protein (VAMP) (8). These interactions form a complete SNARE
complex, facilitate fusion of the two membranes, and permit insulin secretion from the β cell (Figure 1). Proper assembly of these SNARE complexes requires accessory proteins, known as Munc18 proteins. Munc18 proteins bind the t-SNARE and v-SNARE proteins with high affinity (8), but must release their SNARE partners to allow for SNARE complex formation (Figure 1). To accomplish this, double C2-domain protein β (Doc2b) competes with SNARE proteins (9,10) and binds to Munc18 proteins (11,12) (Figure 1). Therefore, Doc2b serves as a temporary docking platform for Munc18 proteins, releasing the t-SNARE and v-SNARE proteins for complex formation, allowing granule fusion with the plasma membrane and insulin secretion. t-SNARE, Target membrane SNARE; v-SNARE, vesicle-associated SNARE; SNAP25, synaptosomal-associated protein 25; VAMP, vesicle-associated membrane protein; Doc2b, double C2-domain protein β.

Previous work by these authors established a correlation between Doc2b expression and β cell function. Aslamy et al. showed that the remaining β cells in the islets of new-onset T1D patients exhibit reduced Doc2b expression (14). Furthermore, incubation of non-diabetic human islets with pro-inflammatory cytokines ex vivo, a condition intended to mimic the inflammatory milieu that destroys islets in vivo, reduced Doc2b expression (14). Conversely, overexpression of Doc2b in MIN6 insulinoma cells increased insulin secretion in vitro (10,15), and overexpression of Doc2b in the pancreas, skeletal muscle, and adipose tissue in vivo increased glucose-stimulated insulin secretion and improved whole-body glucose homeostasis and insulin sensitivity (16). Together, these studies suggest that modulation through Doc2b could be beneficial in maintaining β cell mass in the autoimmune prone individuals, but the mechanisms by which Doc2b promotes β cells health remained unknown.

In their new manuscript (13), Aslamy et al. confirm previous findings and explore more precisely the mechanisms by which Doc2b promotes β cell health and function. In this study, the authors first generated

---

**Figure 1** Doc2b sequesters Munc18 to facilitate SNARE complex formation and insulin secretion. Individual SNARE proteins are anchored in the two membranes. t-SNARE proteins, syntaxin and SNAP25 reside in the plasma membrane, and v-SNARE protein, VAMP, resides in the insulin granule membrane. Munc18 proteins bind the t-SNARE and v-SNARE proteins with high affinity, inhibiting SNARE complex formation. Doc2b competes with SNARE proteins and binds to Munc18 proteins, releasing the t-SNARE and v-SNARE proteins for complex formation, allowing granule fusion with the plasma membrane and insulin secretion. t-SNARE, Target membrane SNARE; v-SNARE, vesicle-associated SNARE; SNAP25, synaptosomal-associated protein 25; VAMP, vesicle-associated membrane protein; Doc2b, double C2-domain protein β.
a doxycycline-induced β cell-specific double transgenic mouse model (βDoc2b-dTg). When these mice were exposed to doxycycline in their drinking water, Doc2b was overexpressed specifically in β cells by 4–5-fold compared to mice not given doxycycline (13). These doxycycline-treated mice exhibited higher insulin secretion and improved glucose tolerance than untreated mice during intraperitoneal glucose tolerance tests (IPGTT). Furthermore, when exposed to multiple-low-dose streptozotocin (MLD-STZ), Doc2b-overexpressing mice showed reduced β cell apoptosis, increased β cell mass, and increased serum insulin compared to control mice (13). Together, data confirmed prior observations in mice, establishing that Doc2b overexpression can be driven in multiple tissues (16). More importantly, these experiments demonstrated that overexpression of Doc2b exclusively in β cells increases insulin secretion and improves whole body glucose homeostasis (13).

To explore the anti-apoptotic effects of Doc2b in β cells, the authors transduced INS-1 insulinoma cells with adenovirus particles encoding Doc2b. When incubated with inflammatory cytokines, INS-1 cells overexpressing Doc2b showed reduced endoplasmic reticulum (ER) stress and apoptosis compared to control cells (13). These data confirm the observations made with the βDoc2b-dTg mice and demonstrate that overexpression of Doc2b improves β cell health and viability, even in the face of inflammatory insult (13). The authors then examined Doc2b proteins mutated by truncation of the Munc18-interacting domain (MID) domain or by single amino acid substitutions that obliterate calcium binding ability of C2A and C2B to determine the domain(s) most important for the protective effects of Doc2b. INS-1 cells were transfected with plasmids encoding these mutated proteins and first exposed to ER stress trigger Thapsigargin to test the efficacy of these mutated proteins in preventing apoptosis. Interestingly, the calcium-binding C2A and C2B were sufficient to protect INS-1 cells from apoptosis, since overexpression of a truncated protein containing only both C2 domains together (C2AB) reduced apoptosis to the same levels as the whole Doc2b protein. Importantly, this anti-apoptotic role was lost when the calcium-binding sites were disrupted by amino acid substitutions, demonstrating the importance of calcium for the protective effect (13).

Finally, the authors demonstrated that the C2AB is sufficient to improve β cell function and insulin secretion. Expression of C2AB, but not C2A or C2B separately, improved glucose-stimulated insulin secretion to similar levels as whole Doc2b in both MIN6 and INS-1 insulinoma cells. This supports previous work that the C2AB, but not C2A or C2B separately, create a ring-shaped oligomer that regulates membrane fusion (17,18). The authors also confirmed that C2AB was sufficient to activate the t-SNARE protein syntaxin 4, demonstrating that C2AB can facilitate the formation of complete SNARE complexes, and providing a mechanism to explain how these domains improve β cell insulin secretion (13).

The findings presented in this publication are exciting, since they reveal a promising new therapeutic avenue for promoting β cell function and preventing β cell apoptosis in those at risk for T1D. However, a few questions remain to be answered before these findings can be translated to the clinic. Given that calcium binding was essential for the anti-apoptotic activity of Doc2b, it would be of interest to further explore whether calcium binding to Doc2b directly modulates its activity or whether binding to C2AB depletes calcium levels, leading to reduced calcium-associated stress and enzymatic activity. C2AB facilitated SNARE complex formation and recapitulated many of the beneficial effects of Doc2b, but lacks the MID domain. Therefore, the functional role of that domain remains unclear. In neuronal studies, the C2A domain of Doc2b was suggested to interact directly with the plasma membrane in a Ca\(^{2+}\)-dependent manner, promoting exocytosis by improving the kinetics of vesicle fusion (19). Consequently, there is some risk that Doc2b overexpression could lead to excessive insulin secretion in some scenarios. The authors propose that Doc2b sequesters Ca\(^{2+}\), preventing ER stress and downmodulating the unfolded protein response (UPR). Indeed, several lines of evidence support a role for ER stress and interaction with the UPR to promote β cell dysfunction and apoptosis (20). However, the authors don’t show any data to directly support modulation of the UPR by Doc2b. Furthermore, experiments showing reduced ER stress and reduced apoptosis did not explore precisely how Doc2b reduces these processes or how its activity may influence enzymatic processes that were recently shown to directly modulate the immunogenicity of self-proteins (21). More mechanistic studies could shed additional light on how this protein interacts with these pathways (directly or indirectly) to protect β cells. Indeed, since overexpression or administration of Doc2b reduces apoptosis after inflammatory cytokine exposure, and given that β cells exhibit increased immunogenicity as a consequence of ER stress (21,22), Doc2b therapy may have the added benefit of reducing autoimmune targeting of β cells by autoreactive
CD4+ and CD8+ T cells. Consequently, studies aimed at the effects of Doc2b overexpression on β cell immunogenicity could provide important insights.

One crucial consideration would be how best to apply Doc2b therapy as a clinical intervention. Systemic administration of C2AB as a peptide/protein therapeutic would likely be problematic, as off-target neurologic effects could be anticipated. Based on the work of Xiao et al., adenovirus gene therapy can be effectively targeted to the pancreas (23). However, barriers (most notably safety concerns) exist for clinical application of adenovirus based approaches. A more plausible option might be to utilize a DNA vaccine, as effectively implemented by Roep et al. for plasmid encoded proinsulin (24). In any case, it seems likely that driving expression of C2AB within the islets of new onset patients or subjects at risk for T1D could provide protection from apoptosis and enhance β cell function.

In summary, this interesting article highlights a role for Doc2b interactions with SNARE complexes to block apoptosis and rejuvenate insulin secretion by pancreatic β cells. Although further questions remain about the mechanisms of these effects, refinement of therapeutic strategies to harness these protective effects could be a major step forward toward effective treatment and prevention of T1D.

Acknowledgements

Funding: This work was supported in part by Children’s Hospital of Pittsburgh of the UPMC Health System [Cochrane-Weber Endowed Fund to ML Marré], National Institutes of Health [grant number 5R01DK099257-03 to JD Piganelli]; Juvenile Diabetes Research Foundation [grant number 1-SRA-2017-344-S-B and 2-SRA-2018-551-S-B to EA James]; and American Diabetes Association [grant number 1-17-IBS-129 to JD Piganelli].

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

15. Miyazaki M, Emoto M, Fukuda N, et al. DOC2b is a SNARE regulator of glucose-stimulated delayed insulin

Cite this article as: Marré ML, Piganelli JD, James EA. Protecting functional β cells with a therapeutic peptide. Ann Transl Med 2018;6(18):372. doi: 10.21037/atm.2018.07.26